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Microabstract 
In this study we have demonstrated a significant difference in the risk factors for arterial and venous thrombosis in 
MPN patients, as well as between different subtypes of MPN, according to leukocyte and platelet count, V617F 
burden allele and cardiovascular risk factors. 
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Abstract 
 
INTRODUCTION: Thrombosis is the most common complication in Ph(-) MPN patients. 
PATIENTS AND METHODS: In a cohort of 258 Ph(-) MPN patients, the difference between patients with and without 
thrombosis was analysed according to genetic thrombophilia factors, JAK2 V617F status and burden allele, blood 
count, cardiovascular risk factors and age. Patients were also divided in PV, ET and PMF subgroups and by the type of 
thrombosis.  
RESULTS: Analysis of cardiovascular risk factors regarding arterial thrombosis showed that PV patients with 
thrombosis had higher incidence of diabetes (p=0.030), ET patients had more often hypertension (p=0.003) and 
hyperlipidemia (p=0.005) while PMF patients had hyperlipidemia (p=0.046) and at least one cardiovascular risk factor 
(p=0.044). Moreover, leukocytes >18x10e9/L and V617F burden allele >25.7% were statistically significantly different 
in PV patients (p=0.019 and borderline significance p=0.055, respectively), while in ET patients leukocytes 
>9.2x10e9/L (p<0.001) and age at diagnosis >55 years were statistically significantly different (p=0.002). PMF patients 
with V617F burden allele ≤34.8% were more prone to thrombosis (p= 0.032). When comparing patients with and 
without venous thrombosis, cut-off value of V617F burden allele >90.4% was significant for PV patients with 
thrombosis (p=0.036), as was >56.7% for PMF patients with thrombosis (p=0.046). Platelets ≤536x10e9/L and age at 
diagnosis >54 years showed statistically significant difference for ET patients with thrombosis (p= 0.015 and p=0.041, 
respectively). 
CONCLUSION: Based on our results, a new scoring system for thrombosis risk in PV could be made while PMF 
prognostic model may be expanded for better recognition of potential thrombotic risk factors. 
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Introduction 
Philadelphia chromosome negative myeloproliferative neoplasms (Ph(–)MPN) are a group of clonal hematopoietic 
diseases including polycythemia vera (PV), essential  thrombocythemia (ET) and primary myelofibrosis (PMF). Besides 
Calreticulin and MPL mutations, the hallmark of MPN is the V617F JAK2 mutation that is positive in 95% of PV 
patients, 50% of ET patients and 50% of PMF patients 1.  MPNs are thought to be very rare diseases with an incidence 
of 0.5-2.2 for ET, 0.6-2.8 for PV and 0.3-1.9 for PMF per 100 000 2. 
Thrombosis is one of the most common complications of MPN which adds significantly to the increased morbidity 
and mortality rate of patients in all three subgroups of the disease 3. Whether the patient with MPN is more prone to 
thrombosis or bleeding depends on the type of disease, mutation status, number and function of leukocytes, 
erythrocytes and platelets, and finally other cofactors which are partly still unknown. Incidence of thrombosis in  
MPN patients varies from 18.3 to 33.6 %, as was observed in different studies.4,5. Although some risk factors are very 
well known  and are included in clinical evaluation, such as age >65 years and prior history of thrombosis 6,7, 
additional risk factors are still under investigation.  Several studies looked into risk factors for thrombosis in MPN like 
leukocytosis 8,9,16, presence of cardiovascular risk factors 10, V617F burden allele 11, platelet count 12,13,16, hematocrit or 
hemoglobin level 12,13,16, or  thrombophilia genetic factors 14,15 . However, no study analysed all of these factors on the 
same cohort of patients. Moreover, the question whether some of those risk factors contribute only to arterial or also 
venous thrombosis is still open. 
The aim of this study was to describe risk factors for thrombosis in Ph(-) MPN patients, and furthermore analyse risk 
factors typical for each disease subgroup, and also for the type of thrombosis. 
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Patients and Methods 
We conducted a prospective study evaluating 258 MPN patients diagnosed at the University Hospital Center Zagreb 
in the period of six years, between June 2011 and August 2017. All patients were diagnosed according to the 2008 
World Health Organization (WHO) Classification. The patients that were diagnosed as having MPN in another hospital 
were re-evaluated at our Center, including testing for investigated mutations.  
The following parameters were analysed: V617F JAK2 mutation, V617F burden allele, genetic thrombophilia factors 
FV Leiden and PT G20210A mutation, blood count, age at diagnosis, sex, cardiovascular risk factors, thrombotic 
events, timeframe of the first thrombotic event, and current therapy of MPN. All laboratory and genetic testings were 
done at the Department of Laboratory Diagnostics, University Hospital Center Zagreb. Clinical data were taken from 
medical documentation. The study was approved by Ethics Committee of University Hospital Center Zagreb. After 
patients gave their consent, 10 ml of EDTA blood was withdrawn and used for separation of granulocytes from whole 
blood by centrifugation in density gradient with Polymorphprep. Genomic DNA extraction was performed by using 
the standard salting out method 17. 
Analysis of complete blood count, including leukocytes (WBC), erithrocytes (RBC), platelets (PLT) and hemoglobin 
(HGB) concentration was performed for all patients on routine Coulter DxH 800 instrument at the moment of 
inclusion of patients in the study. Testing for V617F JAK2 mutation was done by allele-specific PCR according to 
Baxter et al 1. If positive result was obtained , V617F burden allele was quantified by real time PCR method 
established by Larsen et al 18. Screening for FV Leiden and PT G20210A mutation was done by using RFLP-PCR method 
19,20. Information about thrombotic events in the past, previous and current hematologic therapy, and cardiovascular 
risk factors (CV) which included hypertension, diabetes mellitus, hyperlipidemia, smoking and alcohol usage was 
obtained from medical documentation. During follow up, all thrombotic events were recorded. 
Thrombotic events were diagnosed by standard diagnostic procedures and they were divided into arterial and venous 
thrombosis. Arterial events included ischemic cerebrovascular insult (ICV), transient ischemic attack (TIA), acute 
myocardial infarction (AIM), major peripheral arterial events, splenic infarction and fetal growth restriction. Venous 
thrombotic events were deep venous thrombosis (DVT), pulmonary embolism (PE), splanchnic thrombosis, cerebral 
vein thrombosis, thrombosis of retina vein and superficial thrombophlebitis. 
Statistical analysis was performed by Medcalc v.17.2-64 bit. Normality was checked by Kolmogorov-Smirnov test. If 
data were normally distributed they are presented as mean with standard deviation and compared by t-test for 
unpaired samples. If data were not normal, they are presented as median and interquartile range and Mann Whitney 
test was used for comparison between groups.  For categorical variables, Fisher or Chi-square test was used to 
calculate the p value. Odds ratio was calculated for comparison of categorical data. In univariate analysis, value p≤ 
0.05 is considered statistically significant. Multivariate logistic regression model was used for variables that were 
statistically significant in univariate analysis and results with p≤ 0.1 were considered statistically significant. For 
distinguishing cut-off values of quantitative risk factors between groups of patients, receiver-operating characteristic 
(ROC curve) was used followed by odds ratio calculation. 
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Results 
We identified 258 patients with MPN diagnosis during the study period, including 134 ET (94 females and 40 males, 
median age 55, range 18-92), 70 PV (36 females, 34 males, median age 64, range 29-84 years) and 54 PMF patients 
(24 females, 30 males, median age 62, range 24-85 years). 
Median time from diagnosis to end of this study was 67 months (range 15-463). The median follow-up of patients 
since the study started was 58 months (range 10-74). 
Management of MPN patients included follow-up with no treatment, antiplatelet drugs and/or cytoreductive 
therapy, JAK-2 inhibitor, immunomodulatory therapy, venepuncture, or supportive RBC transfusions.  Thirty-three 
MPN patients were therapy-free. 
Out of 258 evaluated MPN patients, 79 (30.6%) patients developed thrombosis with a total of 109 thrombotic events; 
72 (66.1%) arterial and 37 (33.9%) venous. Twenty (25.3%) patients had two or more thrombotic events and six 
(7.6%) developed both arterial and venous thrombosis. Thrombotic events were more common in PMF (35.2%) and 
PV (34.3%), than in ET patients (26.9%) (Table 1). 
Regarding the analysed risk factors, MPN patients with thrombosis showed higher frequency of V617F JAK2 positivity 
(81% vs 68.2%, p=0.049), higher V617F JAK2 burden allele (30.4% vs 17.0%, p= <0.001), higher WBC count (10.5 vs 9.5 
x109/L, p= 0.009), older age at the time of diagnosis (63 vs 57 years p=0.022), higher incidence of hypertension (73.4% 
vs 49.7%, p= < 0.001), hyperlipidemia (30.4% vs 11.2%, p= <0.001) and presence of least one CV risk factor (83.5% vs 
60.9%, p= 0.001). (Table 1). The type of treatment did not have influence on the occurrence of thrombosis. In 
multivariate analysis, statistically significant difference remained only for hyperlipidemia (OR= 3.2, 95%CI= 1.3-7.6, 
p=0.011). 
The same risk factors were found to be different with statistical significance when arterial thrombosis in MPN 
patients was analysed separately; V617F JAK2 positivity (84.7% vs 68.2%, p=0.021), higher V617F burden allele  
(29.1% vs 17.0%, p= <0.001), higher WBC count  (10.6 vs 9.5 x109/L, p=0.001), older age at diagnosis (65 vs 57 years, 
p=0.008), hypertension and hyperlipidemia (76.3% vs 49.7%, p= <0.001 and 33.9% vs 11.2%, p= <0.001) and presence 
of at least one CV risk factor  (89.8% vs 60.9%, p= <0.001) (Table 1). Multivariate analysis revealed statistical 
significance of hyperlipidemia and CV risk factors (OR=3.3, 95%CI =1.3-8.3, p=0.010 and OR=0.3, 95CI% =0.1-1.3, 
p=0.097). 
On the other hand, analysis of risk factors for venous thrombosis in MPN patients showed statistically significant 
difference for higher V617F burden allele (38.1% vs 17.0%, p=0.003), but lower HGB level (133 vs 144 g/L, p= 0.049) 
and lower PLT count (447 vs 571 x109/L, p=0.011) (Table 1).  In multivariate analysis, V617F burden allele and HGB 
level remained statistically significantly different (OR=1.0, 95CI%=1.0-1.1, p=0.002 and OR=1.0,95 CI%=0.9-1.0, 
p=0.064).  
 
Polycythemia vera patients 
The most frequent type of thrombosis in PV patients was arterial thrombosis (AMI, ICV, TIA, splenic infarction, 
occlusion of femoral arteries) that occurred in 19 (27.1%) patients, compared to venous events (DVT, PE, splanchnic 
thrombosis, cerebral venous thrombosis, peripheral thrombophlebitis) present in eight (11.4%) patients. Three 
patients (4.3%) had both types of thrombosis (combinations of DVT and ICV, cerebral venous thrombosis and fetal 
growth restriction, AMI and DVT). Seven (10.0%) patients had recurrent thrombosis with two or more thrombotic 
events. Eleven out of twenty-four patients (45.8%) developed thrombosis at the time of diagnosis, five patients 
(20.8%) had thrombosis before, and eight (33.3%) after diagnosis. Twelve patients (50.0%) developed thrombosis 
within one year of diagnosis. 
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In the group of PV patients, statistically significant risk parameter for thrombosis was diabetes (33.3% vs 10.9%, 
p=0.048). When analysed separately, diabetes (36.8% vs 10.9%, p=0.030) and presence of at least one CV risk factor 
(94.7% vs 69.6%, p=0.049) showed statistical significance for arterial thrombosis, while there was no statistically 
significant difference between patients with and without venous thrombosis (Table 2). 
In multivariate analysis in PV patients with arterial thrombosis, diabetes remained statistically significant (OR=3.3, 
95%CI= 0.9-12.7, p=0.072). 
 
Essential thrombocythemia patients 
In ET group, 29 (21.6%) patients had 32 arterial thrombotic events (AMI, ICV, TIA, embolization of digital arteries , 
occlusion of femoral arteries, thrombosis of the carotid artery, splenic infarction, and fetal growth restriction), 10 
(7.5%) patients had 14 venous thrombotic events (DVT with or without PE, splanchnic thrombosis, superficial 
thrombophlebitis), while three patients (2.2%) had both arterial and venous thrombosis (thrombosis of an upper 
limb and retinal thrombosis, combination of splenic infarction and deep vein thrombosis or peripheral 
thrombophlebitis). Seven (19.4%) patients had two or more thrombotic events.  
Sixteen out of 36 patients (44.4%) developed thrombosis at the time of diagnosis, 14 (38.9%) patients had thrombosis 
before diagnosis and four patients (16.7%) after. Eighteen patients (50.0%) developed thrombosis within one year of 
diagnosis. 
Statistically significant difference between ET patients with and without thrombosis was found for the frequency of 
V617F JAK2 positivity (77.8% vs 57.1%, p=0.047), higher WBC count (10.2 vs 8.5 x109/L, p=0.010), older age at 
diagnosis (65 vs 52 years, p=0.008), hypertension (72.2% vs 40.8%, p= 0.003), hyperlipidemia (30.6% vs 9.2%, p = 
0.005) and incidence of at least one CV risk factor (86.1% vs 55.1%, p=0.001) (Table 3). After multivariate analysis was 
performed, WBC count, hyperlipidemia and hypertension remained statistically significantly different (OR= 1.2, 
95CI%= 1.0-1.5, p= 0.022, OR=4.0, 95CI%=0.9-18.7, p=0.076 and OR= 4.0, 95CI%= 1.0-15.8, p=0.051, respectively). 
Moreover, all patients with two or more thrombotic events were V617F JAK2 positive. 
Regarding the presence of arterial thrombosis in patients with ET, patients with thrombosis had higher WBC count 
(10.6 vs 8.5 x109/L, p= <0.001), higher PLT count (700 vs 617 x109/L, p= 0.050), were of older age at diagnosis (65 vs 
52 years, p=0.009), had hypertension, hyperlipidemia or at least one CV risk factor (65.5% vs 40.8%, p= 0.021, 31.0% 
vs 9.2%, p=0.006 and 82.8% vs 55.1%, p= 0.009, respectively) (Table 3).  Multivariate analysis showed that statistically 
significant difference was obtained for WBC count and hyperlipidemia (OR = 1.2., 95% CI =1.1-1.4, p= 0.009 and OR= 
3.0, 95CI%=0.9-9.7, p=0.072 respectively). 
All ET patients with venous thrombosis had hypertension, which was also statistically significantly different from 
patients without thrombosis (100.0% vs 40.8%, p= <0.001), also that generated the presence of at least one CV risk 
factor (100.0 vs 55.1%, p=0.005), (Table 3). Multivariate analysis showed no statistically significant difference in the 
results. 
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Primary myelofibrosis patients 
In the group of PMF patients, 19 patients had thrombosis (35.2%), 11 (20.4%) arterial (AIM, ICV, abdominal 
thrombosis, thrombosis of subclavian artery, TIA and splenic infarction) and eight (14.8%) venous (DVT, PE, 
abdominal thrombosis, thrombophlebitis).  Six (11.1%) patients had two or more thrombotic events. 
Three out of 19 patients (15.8%) developed thrombosis at the time of diagnosis, seven (36.8%) had thrombosis before 
diagnosis and nine (47.4%) after diagnosis. Altogether, nine (47.4%) patients developed thrombosis within one year 
of diagnosis. 
Comparing PMF patients with and without thrombosis, we found no statistically significantly different results in any 
of the investigated parameters (Table 4). 
Evaluation of PMF patients with and without arterial thrombosis demonstrated higher incidence of hyperlipidemia 
(36.4% vs 8.5%, p=0.046) and at least one CV risk factor (100.0% vs 65.7%, p=0.044) in patients with thrombosis 
(Table 4). After multivariate analysis none of the parameters remained statistically significant. 
There was no difference observed in any of the investigated parameters for PMF patients with venous thrombosis 
(Table 4). 
 
Cut-off values for quantitative parameters in patients with arterial thrombosis compared to patients without 
thrombosis 
Comparison of MPN patients with and without arterial thrombosis revealed statistically significant difference in 
V617F burden allele >14.6 %, WBC count >9.25x 109/L and age at diagnosis > 55 years (p= 0.011, p=0.003 and 
p=0.006, respectively) (Table 5).  In multivariate analysis, results for V617F burden allele, WBC count and age at 
diagnosis remained statistically significantly different (OR= 0.4, 95%CI = 0.2-0.9, p=0.016; OR= 0.5, 95%CI= 0.2-1.1, 
p=0.079; OR=0.4, 95%CI=0.2-0.9, p= 0.032, respectively). 
In PV patients with arterial thrombosis, WBC count >18 x 109/L was statistically significantly different (p=0.019) while 
V617F burden allele >25.7% showed borderline significance (p=0.055), (Table 5). Multivariate analysis for PV patients 
showed that cut-off values for WBC count and V617F burden allele remained statistically significant (OR=5.5, 
95%CI=0.9-33.3, p=0.063 and OR= 0.2, 95%CI= 0.0-1.1, p=0.069).  
Compared to patients without thrombosis, ET patients with arterial thrombosis had statistically significantly different 
results for V617F burden allele >14.6%, WBC count >9.2 x 109/L, RBC count >5.48 x 1012/L, HGB level >106 g/L, PLT 
count >632 x 109/L and age at diagnosis >55 years (p= 0.021, p<0.001, p=0.046, p=0.028, p=0.049 and p= 0.002, 
respectively), (Table 6).  After multivariate analysis, WBC count and age at diagnosis remained statistically 
significantly different (OR=0.2, 95%CI= 0.0-0.6, p=0.012 and OR=0.06, 95%CI=0.1-0.7, p=0.010). 
In the group of PMF patients with arterial thrombosis, only V617F burden allele ≤ 34.8% showed statistically 
significant difference with p= 0.032, (Table 5). 
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Cut-off values for quantitative parameters in patients with venous thrombosis compared to patients without 
thrombosis 
In all MPN patients, only WBC count >21x 109/L showed statistically significant difference (p=0.036), (Table 6). 
PV patients with V617F burden allele >90.4% and HGB level ≤159 g/L were more prone to venous thrombosis 
(p=0.036 and p= 0.041), (Table 6). In multivariate analysis, HGB level ≤159 g/L remained statistically significantly 
different (OR= 6.4, 95%CI=1.0-39.5, p=0.044). 
For ET patients, PLT count ≤536 x 109/L and age at diagnosis >54 years showed statistically significant difference (p= 
0.015 and p=0.041), (Table 6). After multivariate analysis, both cut-off values for PLT count and age at diagnosis, 
remained statistically significant (OR=10.1, 95%CI=2.1-47.6, p=0.004 and OR=10.0, 95%CI= 1.8-56.6, p=0.009). 
In the group of PMF patients, only V617F burden allele >56.7% was more often observed in patients with venous 
thrombosis (p=0.046), Table 6. 
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Discussion 
Ph(-) MPN patients have higher incidence of thrombosis and bleeding and shorter life expectancy than healthy people 
of the same age 21. Risk factors that contribute to thrombosis in MPN patients are partly known, and were mostly 
investigated in retrospective studies, although mostly for single MPN subgroup, or regarding just arterial or venous 
thrombosis. Here we present a prospective study on the risk factors for thrombosis in MPN patients with the median 
follow-up of 57.5 months. We investigated influence of several risk factors on thrombosis in MPN patients, including 
V617F driver status mutation and burden allele, inherited thrombophilia, blood count parameters and cardiovascular 
risk factors. Furthermore, we evaluated the difference in risk factors depending on the subtype of MPN and type of 
thrombosis due to the proven difference in their pathogenesis and the risk factors present in general population. 
 In our cohort of 258 patients, 79 (30.6%) patients had a total of 109 thrombotic events, 66.1% arterial and 33.9% 
venous, which is consistent with the studies published earlier 8,9,22. Moreover, our results demonstrated that the 
incidence of thrombosis in ET and PV patients was similar to those previously reported 23,24. Actually, 21.6% of our ET 
patients had arterial and 7.5% venous thrombosis, while 27.1% of PV patients had arterial and 11.4% venous 
thrombosis. On the other hand, our results for the PMF patients showed much higher incidence of thrombosis 
(35.2%) than those previously reported by Barbui et al 25 (7.2%). However, the cited study was performed on a larger 
number of patients but with shorter median of follow-up of 35.0 months, with only cardiovascular events during 
follow up included. Our results are also comparable to findings from a study by Buxhofer-Ausch et al 35 where 
thrombotic events were divided to those before diagnosis with the incidence of 15.5% for arterial and 6.4% with 
venous events and those after diagnosis with the incidence of 15.9% for non-fatal and 4.9% fatal thrombotic events. 
Higher incidence of thrombosis in our PMF patients could be result of the small number of patients, longer follow-up, 
or the fact that some of our patients were in prefibrotic phase of PMF when included in the study. 
As reported before, the majority of thrombotic events in MPN patients occur around the time of diagnosis, and are 
often the first symptom related to the diagnosis 26. Our results confirmed this thesis as we found the peak incidence 
of thrombosis to occur one year around the time of diagnosis and with almost Gaussian distribution of thrombotic 
events before and after diagnosis, even after a long follow-up. 
Cardiovascular risk factors such are hypertension, diabetes mellitus, hyperlipidemia, smoking and alcohol usage were 
investigated in different studies with the conclusion that they mainly increase the risk of arterial thrombosis 27,28. 
However, we found only diabetes to be a risk factor for arterial thrombosis in PV and hypertension and 
hyperlipidemia in ET. Interestingly, we noted that all ET patients with venous thrombosis had hypertension; however, 
this influence was lost in multivariate analysis. As for the PMF, available prognostic models do not include 
cardiovascular risk factors 29,30. Correspondingly, we found only hyperlipidemia as a risk factor for arterial thrombosis 
in PMF patients, but only in univariate analysis. The key finding of this observation is that additional CV risk factors 
such are hyperlipidemia, hypertension and diabetes can enhance odds for thrombotic events in MPN patients. This 
could be of crucial clinical interest since majority of additional risk factors could be managed by the change of the 
patient's lifestyle who can thus potentially avoid thrombotic events. 
Several groups of investigators were interested in incidence of inherited thrombophilia factors in MPN patients, but 
the results are inconclusive. Gisslinger et al 31 observed connection between PT G20210A mutation and venous 
thrombosis, while Trifa et al 15 obtained increased incidence of FV Leiden in patients with PV in arterial and venous 
thrombosis, although only in univariate analysis. Similarly, Schwarz et al 13 described FV Leiden as a risk factor for 
both venous and arterial thrombosis in all types of MPNs.  In our study, incidence of heterozygosity for FV Leiden and 
PT G20210A mutation is similar as in healthy population 32 as well as in MPN patients with and without thrombosis.  
The role of molecular thrombophilia screening for FV Leiden and PT G20210A mutation in estimating the risk of 
thrombosis in MPN patients is still unclear and should be further investigated on a larger cohort of patients. 
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Regarding leukocytosis, the majority of investigators found connection between the number of leukocytes and 
incidence of thrombosis, but with different cut-off values for each subtype of MPN disease. For PV patients, Landolfi 
et al 28  found leukocyte count of 15x109/L to be predictive for arterial thrombosis, while Carrobio et al 8 obtained the 
cut-off value of 8.7x109/L as a predictive factor for both arterial and venous thrombosis in ET patients. For PMF 
patients, Barbui et al 25 reported borderline significance for WBC higher than 15x109/L for all cardiovascular events. In 
our study, PV patients with arterial thrombosis had cut-off value for WBC >18x109/L, and ET patients >9.2x109/L both 
statistically significant (p=0.019 and <0.001, respectively). For PMF patients, no statistically significant difference for 
leukocyte number was observed. It seems that thrombogenic effect of leukocytes is more obvious in arterial 
thrombosis than venous, due to the activation of leukocytes, release of proteolytic enzymes and reactive oxygen 
species, that has effect on endothelial cells as well as formation of platelet-leukocyte aggregates which all contribute 
to the occurrence of arterial thrombi 33. 
The influence of platelets on occurrence of thrombosis in MPN patients is still under investigation. Most studies 
report that extreme thrombocytosis reduces the risk for thrombosis in ET 34 and PMF 35. Schwarz et al 13 confirmed 
this in a large study on Ph(-)MPN patients. We observed higher platelet count in ET patients with arterial thrombosis 
compared to ET patients without thrombosis, but this finding lost its significance in multivariate analysis. Moreover, 
the analysis of cut-off values demonstrated that PLT count in ET patients >632x109/L was significant for arterial 
thrombosis, while patients with PLT count ≤536 x 109/L were more prone to venous thrombosis. This finding clearly 
shows that same cells can contribute differently to occurrence of arterial and venous thrombosis. 
Older age is an established thrombotic risk factor in both general population 36 and MPN patients 6,34,25. For ET 
patients, IPSET scoring system considers age over 60 years as one of thrombotic risk factors 37. The same age was also 
observed as a thrombotic risk factor for PMF patients 25, while slightly higher age of >65 years was in PV patients 
related to higher mortality 6.  Our results suggest even lower cut-off value for the age of MPN patients with risk of 
thrombosis. We found age >55 years to be a significant risk factor for arterial thrombosis in all MPN patients, as well 
as for a subgroup of ET patients. As for the risk of venous thrombosis, we found significant influence of age only in ET 
patients, with the cut-off value of >54 years. Based on this finding, we should emphasize the importance of age as a 
predictive factor for thrombosis. Overall, age is one of the parameters that should be included into scoring system for 
all MPN entities. 
Driver mutation V617F JAK2 and V617F burden allele are important risk factors investigated since this mutation was 
discovered in 2005 1. Authors of IPSET scoring system also recognized the presence of V617F mutation as one of 
thrombosis contributing factors 37. Although the presence of this mutation is much higher in PV than in ET and PMF 
patients, some studies showed that additional information can be obtained from quantifying V617F burden allele in 
each of the MPN subgroups 38,39. For PV patients, Vannuchi et al 38 reported the value of burden allele >75% to be 
predictive for thrombosis. Our findings suggest different cut-off values for arterial and venous thrombosis in PV. 
Burden allele >25.7% showed borderline significance for arterial thrombosis in PV patients, while patients with 
venous thrombosis had burden allele >90.4%. Regarding the ET, Antonioli et al 39  found that burden allele >25%  is 
related to an increased incidence of arterial thrombosis, while we found this relation for even lower values, i.e. 
>14,6%. In PMF patients, quantification of burden allele is mostly used to predict poor survival 40. However, we 
observed for the first time that PMF patients had more often arterial thrombosis if their burden allele was ≤34.8% 
and venous thrombosis with burden allele >56.7%. These findings suggest different influence of burden allele on 
pathophysiology of arterial and venous thrombosis in MPN. Patients with arterial thrombosis, unlike those with 
venous thrombosis, had mostly lower burden allele in all MPN subgroups. 
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Conclusion 
This study investigated influence of thrombotic risk factors on incidence of arterial and venous thrombosis in MPN 
patients. We found significant difference between risk factors causing arterial and venous thrombosis, specifically in 
leukocyte and platelet count, V617F burden allele and additional cardiovascular risk factors. Importantly, risk factors 
for arterial thrombosis could be at least partly preventable through the change of lifestyle, while risk factors for 
venous thrombosis depend mostly on the features of myeloproliferative disease. Furthermore, it should be 
highlighted that each subtype of MPN has its specific risk factors, implying different pathogenesis. 
In conclusion, based on our results, an introduction of a new scoring system for thrombosis risk in PV could be made, 
while current prognostic model for PMF may be expanded for better recognition of potential thrombotic risk factors. 
However, the influence of certain risk factors on occurrence of thrombosis in MPN is still unclear and should be 
addressed on larger cohorts of patients. 
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Clinical Practice Points 
Ph(-) MPN patients have higher mortality than healthy people due to their predisposition to thrombosis, bleeding or 
transformation of disease. Here we introduce new findings about differences in patients with and without thrombosis 
as well as differences in risk factors for arterial versus venous thrombosis. This knowledge may help to better 
recognize important risk factors that can influence thrombosis occurrence and give directions for new risk 
stratification models in PV and PMF patients. 
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Table 1.  Comparison of MPN patients with or without thrombosis regarding risk parameters. 
All MPN patients, N=258 
Risk factor 
Patients with 
thrombosis  
N=79             
(30.6%) 
No thrombosis 
patients  
N=179  
(69.4%) 
OR 
 (CI) 
p value 
Arterial 
thrombosis 
patients, 
N=59 
 (22.9%) 
 
OR  
(CI) 
*p value 
Venous 
thrombosis 
patients, 
N=26 
 (10.1%) 
 
OR  
(CI) 
**p value 
FV Leiden mutation 
heterozygote, N (%) 
4 (5.1) 7 (3.9) 
1.3 
(0.4-4.6) 
0.741 2 (3.4) 
0.9 
(0.2-4.3) 
1.0 2 (7.7) 
2.0 
(0.4-10.4) 
0.319 
FII G20210A 
heterozygote, N (%) 
0 (0) 5 (2.8) 
0.2 
(0.0-3.7) 
0.327 0 (0.0) 
0.3 
(0.0-4.9) 
0.336 0 (0.) 
0.6 
(0.0-11.1) 
1.0 
V617F JAK2 
mutation positive,  
N (%) 
64 (81.0) 122 (68.2) 
2.0 
(1.0-3.8) 
0.049 50 (84.7) 
2.6 
(1.2-5.6) 
0.021 20 (76.9) 
1.6 
(0.6-4.1) 
0.498 
V617F JAK2 
burden allele %, 
median  
(1.-3.quartile) 
30.4 
(15.9-59.7) 
17.0 
(8.4-32.3) 
 <0.001 
29.1  
(15.7-51.5) 
 <0.001 
38.1 
(19.2-84.8) 
 0.003 
WBCx109/L, 
median (1.-3.quartile) 
10.5 
(8.3-14.7) 
9.5 
(7.2-12.1) 
 0.009 
10.6 
 (9.0-14.7) 
 0.001 
9.7 
(6.4-14.9) 
 0.591 
RBCx1012/L, 
mean (± sd) 
5.02 
(±1.29) 
5.09 
(±1.12) 
 0.692 5.17 (± 1.28)  0.634 4.78 (±1.27)  0.204 
HGB g/L, 
mean (± sd) 
141 
(±32) 
144 
(±26) 
 0.409 146 (±32)  0.666 133 (±30)  0.049 
PLT x109/L, 
median (1.-3.quartile) 
551  
(376-685) 
571 
 (437-720) 
 0.229 
568  
(404-734) 
 0.884 
447 
(349-586) 
 0.011 
Age, years, 
median (range) 
63 
(23-92) 
57 
(18-90) 
 0.022 
65 
(55-74) 
 0.008 
59 
(51-65) 
 0.658 
Male, N (%) 38 (48.1) 66 (36.9) 
1.6 
(0.9-2.7) 
0.119 28 (47.5) 
1.5 
(0.9-2.8) 
0.197 12 (46.2) 
0.9 
(0.4-1.8) 
0.831 
Smoking, N (%) 13 (16.5) 23 (12.8) 
1.3 
(0.6-2.8) 
0.565 13 (22.0) 
1.9 
(0.9-4.1) 
0.097 1 (3.8) 
0.3 
(0.0-2.1) 
0.324 
Alcoholism, N (%) 1 (1.3) 1 (0.6) 
2.3 
(0.1-37.0) 
0.519 1 (1.7) 
3.1 
(0.2-49.8) 
0.435 0 (0.0) 
2.2 
(0.1-56.6) 
1.0 
Hypertension, N (%) 58 (73.4) 89 (49.7) 
2.8 
(1.6-5.0) 
<0.001 45 (76.3) 
3.3 
(1.7-6.3) 
<0.001 18 (69.2) 
2.3 
(0.9-5.5) 
0.099 
Diabetes, N (%) 16 (20.3) 24 (13.4) 
1.6 
(0.8-3.3) 
0.225 14 (23.7) 
2.0 
(1.0-4.2) 
0.095 3 (11.5) 
0.8 
(0.2-3.0) 
1.0 
Hyperlipidemia, N (%) 24 (30.4) 20 (11.2) 
3.5 
(1.8-6.8) 
<0.001 20 (33.9) 
4.1 
(2.0-8.3) 
<0.001 5 (19.2) 
1.5 
(0.5-4.5) 
0.330 
At least one CV risk 
factor, N (%) 
66 (83.5) 109 (60.9) 
3.2  
(1.7-6.3) 
0.001 53 (89.8) 
5.7 
(2.3-13.9) 
<0.001 18 (69.2) 
1.4 
(0.6-3.5) 
0.547 
* for comparison of MPN patients with arterial thrombosis to MPN patients that had no thrombosis; ** for comparison of MPN patients with venous thrombosis to MPN patients that had no thrombosis 
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Table 2. Comparison of PV patients with or without thrombosis regarding risk parameters. 
PV patients, N=70 
Risk factor 
 
Patients with 
thrombosis, 
N=24  
(34.3%) 
 
No thrombosis 
patients, 
N=46 
 (65.7%) 
OR  
(CI) 
p value 
Arterial 
thrombosis 
patients 
N=19 
 (27.1%) 
OR  
(CI) 
*p value 
Venous 
thrombosis 
patients, 
N=8 
 (11.4%) 
OR  
(CI) 
**p value 
FV Leiden mutation 
heterozygote, N (%) 
0 (0.0) 3 (6.5) 
0.3 
(0.0-5.1) 
0.546 0 (0.0) 
0.3 
(0.0-6.5) 
0.550 0 (0.0) 
1.2 
(0.3-5.3) 
 
1.000 
FII G20210A 
heterozygote, N (%) 
0 (0.0) 1 (2.2) 
0.6 
(0.0-15.8) 
1.000 0 (0.0) 
0.8 
(0.0-19.9) 
1.000 0 (0.0) 
1.8 
(0.1-47.6) 
 
1.000 
V617F JAK2 
mutation positive,  
N (%) 
22 (91.7) 44 (95.7) 
0.5 
(0.1-3.8) 
0.889 17 (89.5) 
0.4 
(0.0-3.0) 
0.574 8 (100.0) 
1.0 
(0.0-21.7) 
 
1.000 
V617F JAK2 
burden allele % 
median  
(1.-3.quartile) 
51.2 
(32.5-90.9) 
37.6 
(15.8-70.0) 
 0.089 
55.1 
(34.8-86.3) 
 0.082 
41.5 
(27.6-94.0) 
 0.348 
WBCx109/L, 
median (1.-3.quartile) 
11.4 
(9.0-18.4) 
10.9 
(8.5-13.5) 
 0.276 
12.2 
(9.0-18.4) 
 
0.223 
11.4 
(8.7-19.9) 
 0.636 
RBCx1012/L, 
mean (± sd) 
6.28 
(±1.05) 
6.38 
(±0.96) 
 0.692 
6.34 
(±1.14) 
 
0.896 
6.07 (±0.51)  0.412 
HGB g/L, 
mean (± sd) 
166 
(±27) 
172 
(±18) 
 0.353 172 (±25)  
0.115 
156 (±27.7)  0.058 
PLT x109/L, 
median  (1.-3.quartile) 
430 
(375-594) 
516 
(367-674) 
 0.252 
468 
 (377-594) 
 
0.342 
381 
(373-576) 
 0.259 
Age, years, 
median (range) 
64 
(29-81) 
64 
(31-84) 
 0.785 
64 
 (34-81) 
 
0.423 
58 
(29-69) 
 0.128 
Male, N (%) 
13 (54.2) 21 (45.7) 
1.4 
(0.5-3.8) 
0.671 10 (52.6) 
1.3 
(0.5-3.9) 
0.785 4 (50.0) 
1.2 
(0.3-5.3) 
1.000 
Smoking, N (%) 
3 (12.5) 5 (11.1) 
1.2 
(0.3-5.4) 
1.000 3 (15.8) 
1.5 
(0.3-7.2) 
0.683 0 (0.0) 
0.4 
(0.0-8.8) 
1.000 
Alcoholism, N (%) 
1 (4.2) 1 (2.2) 
1.9 
(0.1-31.3) 
1.000 1 (5.3) 
2.5 
(0.1-42.2) 
0.502 0 (0.0) 
1.8 
(0.1-47.6) 
1.000 
Hypertension, N (%) 
19 (79.2) 30 (65.2) 
2.0 
(0.6-6.4) 
0.280 17 (89.5) 
4.5 
(0.9-22.1) 
0.067 4 (50.0) 
0.5 
(0.1-2.4) 
0.450 
Diabetes, N (%) 
8 (33.3) 5 (10.9) 
4.1 
(1.2-14.4) 
0.048 7 (36.8) 
4.8 
(1.3-17.8) 
0.030 1 (12.5) 
1.2 
(0.1-11.6) 
1.000 
Hyperlipidemia, N (%) 
8 (33.3) 8 (17.4) 
2.4 
(0.8-7.4) 
0.227 7 (36.8) 
2.8 
(0.8-9.2) 
0.112 1 (12.5) 
0.7 
(0.1-6.3) 
1.000 
At least one CV risk factor, 
N (%) 
20 (83.3) 32 (69.6) 
2.2 
(0.6-7.6) 
0.259 18 (94.7) 
7.9 
(1.0-64.9) 
0.049 4 (50.0) 
0.4 
(0.1-2.0) 
0.418 
* for comparison of PV patients with arterial thrombosis to PV patients that had no thrombosis; ** for comparison of PV patients with venous thrombosis to PV patients that had no thrombosis 
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Table 3. Comparison of ET patients with or without thrombosis regarding risk parameters. 
ET patients, N= 134 
Risk factor 
Patients with 
thrombosis, 
N=36 
(26.9%) 
No thrombosis 
patients, 
N=98 
 (73.1%) 
OR  
(CI) 
p value 
Arterial 
thrombosis 
patients, 
N=29  
(21.6%) 
OR  
(CI) 
*p value 
Venous 
thrombosis 
patients, 
N=10 
 (7.5%) 
OR  
(CI) 
**p value 
FV Leiden mutation 
heterozygote, N (%) 
2 (5.6%) 4 (4.1%) 
1.4 
(0.2-7.9) 
0.659 1 (3.4) 
0.8 
 (0.1-7.8) 
1.000 1 (10.0) 
2.6  
(0.3-25.9) 
0.391 
FII G20210A 
heterozygote, N (%) 
0 (0.0%) 3 (3.1%) 
0.4 
(0.0-7.4) 
0.564 0 (0.0) 
0.5 
 (0.0-9.2) 
1.000 0 (0.0) 
1.3 
 (0.1-26.9) 
1.000 
V617F JAK2 
mutation positive, 
N (%) 
28 (77.8) 56 (57.1%) 
2.6 
(1.1-6.3) 
0.047 24 (82.8) 
3.6 
 (1.3-10.2) 
0.015 7 (70.0) 
1.8  
(0.4-7.1) 
0.517 
V617F JAK2 
burden allele % 
median  
(1.-3.quartile) 
19.3 
(10.3-27.7) 
16.7 
(9.2-24.7) 
 0.253 
19.8 
 (11.2-30.2) 
 0.140 
18.7 
 (8.8-24.9) 
 0.948 
WBCx109/L, 
median (1.-3.quartile) 
10.2 
(8.6-13.5) 
8.5 
(7.0-10.9) 
 0.010 
10.6  
(9.7-14.0) 
 <0.001 
8.6  
(5.9-10.4) 
 0.840 
RBCx1012/L, 
 mean (± sd) 
4.68 
 (±0.89) 
4.68 
(±0.66) 
 0.964 
4.82  
(±0.90) 
 0.500 
4.54 
 (± 0.90) 
 0.517 
HGB g/L, 
mean (± sd) 
136 
(±27) 
136 
(±19) 
 0.938 136 (±29)  0.949 135 (±20)  0.823 
PLT x109/L, 
median (1.-3.quartile) 
657 
(543-850) 
617 
(526-745) 
 0.576 
700 
 (571-910) 
 0.050 
492 
 (444-707) 
 0.074 
Age, years, 
median (range) 
65 
(23-92) 
52 
(18-90) 
 0.008 
65  
(23-92) 
 0.009 
63 
 (38-82) 
 0.079 
Male, N (%) 14 (38.9) 26 (26.5) 
1.8 
(0.8-3.9) 
0.241 12 (41.4) 
2.0  
(0.8-4.6) 
0.166 3 (30) 
1.2  
(0.3-4.9) 
1.000 
Smoking, N (%) 8 (22.2) 13 (13.3) 
1.9 
(0.7-5.0) 
0.319 8 (27.6) 
2.5 
 (0.9-6.8) 
0.088 1 (10) 
0.7  
(0.1-6.2) 
1.000 
Alcoholism, N (%) 0 (0.0) 0 (0.0) 
2.7 
(0.1-138.5) 
1.000 0 (0.0) 
3.3 
 (0.1-171.9) 
1.000 0 (0.0) 
9.5  
(0.2-502.7) 
1.000 
Hypertension, N (%) 26 (72.2) 40 (40.8) 
3.8 
(1.6-8.7) 
0.003 19 (65.5) 
2.8 
 (1.2-6.5) 
0.021 10 (100.0) 
30.3  
(1.7-532.4) 
<0.001 
Diabetes, N (%) 6 (16.7) 10 (10.2) 
1.8 
(0.6-5.2) 
0.470 6 (20.7) 
2.3  
(0.8-7.0) 
0.198 1 (10.0) 
1.0  
(0.1-8.5) 
1.000 
Hyperlipidemia, N (%) 11 (30.6) 9 (9.2) 
3.1 
(1.2-8.1) 
0.005 9 (31.0) 
4.5  
(1.6-12.6) 
0.006 3 (30.0) 
4.2  
(0.9-19.3) 
0.081 
At least one CV risk 
factor, N (%) 
31 (86.1) 54 (55.1) 
5.1 
(1.8-14.1) 
0.001 24 (82.8) 
3.9 
 (1.4-11.1) 
0.009 10 (100.0) 
17.1 
(1.0-300.8) 
0.005 
* for comparison of ET patients with arterial thrombosis to ET patients that had no thrombosis; ** for comparison of ET patients with venous thrombosis to ET patients that had no thrombosis 
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Table 4. Comparison of PMF patients with or without thrombosis regarding risk parameters. 
PMF patients, N= 54 
Risk factor 
Patients with 
thrombosis, 
N=19 (35.2%) 
No thrombosis 
patients, 
N=35 (64.8%) 
OR 
(CI) 
p value 
Arterial 
thrombosis 
patients, 
N=11 (20.4%) 
OR (CI) *p value 
Venous 
thrombosis 
patients, 
N=8 (14.8%) 
OR (CI) *p value 
FV Leiden mutation 
heterozygote, N (%) 
2 (10.5%) 0 (0.0) 
10.1 
(0.5-222.9) 
0.119 1 (9.1) 
10.1 
(0.4-267.9) 
0.239 1 (12.5) 
14.2  
(0.5-383.5) 
0.186 
FII G20210A 
heterozygote, N (%) 
0 (0.0 %) 1 (2.9) 
0.6 
(0.0-15.2) 
1.000 0 (0.0) 
1.0 
(0.0-26.3) 
1.0 0 (0.0) 
1.4 
(0.1-36.2) 
1.0 
V617F JAK2 
mutation positive, N (%) 
14 (73.7%) 22 (62.9) 
1.7 
(0.5-5.7) 
0.550 9 (81.8) 
2.7 
(0.5-14.2) 
0.296 5 (62.5) 
1.0 
(0.2-4.8) 
1.0 
V617F JAK2 
burden allele % 
median (1.-3.quartile) 
35.1 
(23.1-83.9) 
36.5 
(22.4-56.7) 
 0.795 
29.3 
(14.0-47.1) 
 0.361 
80.5 
(56.9-85.3) 
 0.070 
WBCx109/L, 
median (1.-3.quartile) 
9.5 
(6.9-22.8) 
9.0 
(6.1-15.3) 
 0.556 
9.4 
(7.1-18.8) 
 0.690 
10.3 
(6.4-31.8) 
 0.596 
RBCx1012/L, 
mean (± sd) 
4.16 
 (±1.11) 
4.52 
(±1.04) 
 0.246 4.32 (±0.97)  0.582 3.94 (±1.31)  0.186 
HGB g/L, 
mean (± sd) 
120 
(±27) 
129 
(±27) 
 0.241 128 (±24)  0.871 109 (±29)  0.074 
PLT x109/L, 
median (1.-3.quartile) 
278 
(198-562) 
365 
(209-597) 
 0.415 
278 
(204-547) 
 0.554 
333  
(137-556) 
 0.492 
Age, years, 
median (range) 
58 
(30-81) 
63 
(24-85) 
 0.821 
71 
(30-81) 
 0.928 
57 
(44-79) 
 0.618 
Male, N (%) 11 (57.9) 19 (54.3) 
1.2 
(0.4-3.6) 
0.975 6 (54.5) 
1.0  
(0.3-3.9) 
1.0 5 (62.5) 
1.4 
 (0.3-6.8) 
1.0 
Smoking, N (%) 1 (5.3) 5 (14.3) 
0.3 
(0.0-3.1) 
0.408 2 (18.2) 
1.3  
(0.2-8.1) 
1.0 0 (0.0) 
0.3 
 (0.0-6.5) 
0.565 
Alcoholism, N (%) 0 (0.0%) 0 (0.0) 
1.8 
(0.0-95.4) 
1.000 0 (0.0) 
3.1 
 (0.1-164.5) 
1.0 0 (0.0) 
4.2 
 (0.1-225.9) 
1.0 
Hypertension, N (%) 13 (68.4) 20 (57.1) 
1.6 
(0.5-5.3) 
0.603 9 (81.8) 
3.4  
(0.6-18.0) 
0.172 4 (50.0) 
0.8 
 (0.2-3.5) 
1.0 
Diabetes, N (%) 2 (10.5) 9 (25.7) 
0.3 
(0.1-1.8) 
0.292 1 (9.1) 
0.3  
(0.0-2.6) 
0.410 1 (12.5) 
0.4  
(0.0-3.8) 
0.656 
Hyperlipidemia, N (%) 5 (26.3) 3 (8.5) 
3.8 
(0.8-18.2) 
0.113 4 (36.4) 
6.1  
(1.1-33.6) 
0.046 1 (12.5) 
0.4 
 (0.0-3.8) 
1.0 
At least one CV risk 
factor, N (%) 
15 (78.9) 23 (65.7) 
2.0 
(0.5-7.2) 
0.365 11 (100.0) 
12.2  
(0.7-225.3) 
0.044 4 (50.0) 
0.5  
(0.1-2.5) 
0.443 
* in the comparison of PMF patients with arterial thrombosis to PMF patients that had no thrombosis; ** in the comparison of PMF patients with venous thrombosis to PMF patients that had no thrombosis 
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Table 5. Cut-off values for quantitative parameters in patients with arterial thrombosis compared to patients without thrombosis 
 
 
Risk factor 
All MPN patients  PV patients ET patients 
 
PMF patients 
 
 
Cut-off 
value for 
patients 
with 
arterial 
thrombosis,    
N=59 
OR 
(CI) 
p value 
 
Cut-off 
value for 
patients 
with 
arterial 
thrombosis, 
N=19 
OR 
(CI) 
p value 
Cut-off 
value for 
patients 
with 
arterial 
thrombosis, 
N=29 
OR 
(CI) 
p value 
Cut-off 
value for 
patients 
with 
arterial 
thrombosis,
N=11 
OR 
(CI) 
p value 
V617F JAK2 
burden allele % 
> 14.6 
2.3  
(1.3-4.3) 
0.011 > 25.7 
3.4  
(1.0-11.9) 
0.055 > 14.6 
2.9  
(1.2-6.8) 
0.021 ≤ 34.8 
5.1  
(1.2-21.4) 
0.032 
WBCx109/L > 9.25 
2.8 
 (1.4-5.3) 
0.003 > 18 
7.9 
 (1.4-45.1) 
0.019 > 9.2 
6.1  
(2.1-17.4) 
<0.001 > 6.5 
5.2  
(0.6-45.7) 
0.141 
RBCx1012/L > 4.43 
0.9 
 (0.5-1.6) 
0.768 ≤ 5.45 
3.8 
 (0.9-15.9) 
0.108 > 5.48 
4.0 
 (1.2-13.6) 
0.046 ≤ 2.98 
7.6  
(0.6-93.0) 
0.138 
HGB g/L > 142 
1.6 
 (0.9-2.9) 
0.175 > 191 
3.8 
 (1.0-14.5) 
0.067 > 106 
0.2  
(0.1-0.7) 
0.028 ≤ 158 
6.1 
 (0.3-114.9) 
0.171 
PLTx109/L > 535 
1.4 
 (0.7-2.5) 
0.394 ≤ 640 
4.1 
 (0.8-20.2) 
0.118 > 632 
2.6 
 (1.1-6.3) 
0.049 ≤ 315 
2.6 
 (0.6-10.7) 
0.298 
Age at 
diagnosis, years 
> 55 
2.6 
 (1.3-5.0) 
0.006 > 59 
3.2 
 (0.9-11.0) 
0.093 > 55 
4.6  
(1.8-11.7) 
0.002 > 68 
3.0 
 (0.7-12.1) 
0.153 
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Table 6. Cut-off values for quantitative parameters in patients with venous thrombosis compared to patients without thrombosis 
 
Risk factor All MPN patients  PV patients ET patients 
 
PMF patients 
 
 
Cut-off 
value for 
patients 
with venous 
thrombosis 
N= 26    
OR 
(CI) 
p value 
Cut-off 
value for 
patients 
with venous 
thrombosis 
N=8     
OR 
(CI) 
p value 
Cut-off 
value for 
patients 
with venous 
thrombosis 
N=10     
OR 
(CI) 
p value 
Cut-off 
value for 
patients 
with venous 
thrombosis, 
N=8    
OR 
(CI) 
p value 
V617F JAK2 
burden allele % 
> 26.1 
1.9 
 (0.8-4.3) 
0.193 > 90.4 
1.9 
 (0.4-9.3) 
0.036 > 18.3 
2.1  
(0.5-7.9) 
0.281 > 56.7 
6.0 
 (1.1-32.1) 
0.046 
WBCx109/L > 21 
3.6 
 (1.2-11.5) 
0.036 > 18 
7.3 
 (0.9-62.2) 
0.100 ≤ 5.9 
3.1  
(0.8-15.1) 
0.120 > 18.9 
4.7 
 (0.8-27.3) 
0.106 
RBCx1012/L ≤ 3.9 
2.0 
(0.8-5.1) 
0.199 ≤ 6.42 
2.1 
 (0.4-11.6) 
0.461 ≤ 4.23 
2.8 
 (0.7-10.8) 
0.215 ≤ 3.9 
4.8 
 (1.0-24.3) 
0.089 
HGB g/L ≤ 154 
1.3 
(0.5-3.6) 
0.804 ≤ 159 
5.3 
 (1.1-25.8) 
0.041 ≤ 101 
7.9  
(1.2-54.5) 
0.067 ≤ 140 
7.0 
 (0.4-132.6) 
0.165 
PLTx109/L ≤ 462 
1.1 
(0.5-2.2) 
0.967 ≤ 385 
4.2  
(0.9-20.3) 
0.100 ≤ 536 
5.6  
(1.3-23.0) 
0.015 ≤ 218 
2.9 
(0.6-14.0) 
0.217 
Age at 
diagnosis, years 
> 54 
1.4 
(0.6-3.6) 
0.578 ≤ 69 
8.4  
(0.5-154.5) 
0.089 > 54 
5.6 
 (1.1-27.6) 
0.041 ≤ 61 
3.6 
 (0.6-20.2) 
0.240 
